Kamada (NASDAQ:KMDA) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $7.66 and traded as low as $7.30. Kamada shares last traded at $7.31, with a volume of 35,012 shares.

Analysts Set New Price Targets

A number of research firms have commented on KMDA. Wall Street Zen lowered Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Thursday, March 12th. Stifel Nicolaus set a $11.00 target price on Kamada in a research note on Wednesday, March 11th. Finally, Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kamada presently has an average rating of “Buy” and an average price target of $12.00.

Kamada Stock Down 2.4%

The company’s fifty day simple moving average is $7.66 and its 200 day simple moving average is $8.04. The firm has a market capitalization of $420.40 million, a PE ratio of 20.89, a price-to-earnings-growth ratio of 0.69 and a beta of 0.85.

Kamada (NASDAQ:KMDA) last announced its earnings results on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million. Kamada had a return on equity of 7.73% and a net margin of 11.21%. Equities research analysts forecast that Kamada Ltd. will post 0.44 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in Kamada during the first quarter worth about $582,000. Goldman Sachs Group Inc. bought a new position in Kamada during the 1st quarter valued at approximately $497,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Kamada in the 2nd quarter worth about $472,000. Bank of America Corp DE raised its position in shares of Kamada by 201.0% in the 3rd quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 41,111 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Kamada by 25.9% in the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 40,514 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.